Related Experiment Video
Updated: May 13, 2026
08:01
Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
Published on: June 11, 2020
Simvastatin normalizes autonomic neural control in experimental heart failure.
Rainer U Pliquett1, Kurtis G Cornish, Jacob D Peuler
1Department of Physiology and Biophysics, University of Nebraska Medical Center, Omaha, NE 68198-4575, USA.
Circulation
|April 16, 2003
Summary
Statins, like simvastatin, may improve chronic heart failure (CHF) by normalizing sympathetic nervous system activity and baroreflex function, independent of their lipid-lowering effects. This suggests a novel therapeutic approach for CHF management.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Autonomic Neuroscience
Background:
- Statins (HMG-CoA reductase inhibitors) show benefits in chronic heart failure (CHF).
- The impact of statins on autonomic function in CHF is not fully understood.
- Autonomic dysfunction, including sympathetic hyperactivity, is a hallmark of CHF.
Purpose of the Study:
- To investigate the effects of simvastatin on autonomic function in a rabbit model of CHF.
- To assess whether simvastatin influences sympathetic nerve activity and baroreflex sensitivity.
- To determine if these effects are independent of lipid-lowering properties.
Main Methods:
- Chronic heart failure (CHF) was induced in rabbits via ventricular pacing.
- Rabbits received either vehicle or simvastatin (low or high dose).
- Renal sympathetic nerve activity (RSNA), plasma norepinephrine, and baroreflex function were measured in conscious animals.
Main Results:
- Baseline RSNA and norepinephrine levels were elevated in CHF rabbits.
- High-dose simvastatin significantly reduced RSNA and plasma norepinephrine in CHF rabbits.
- Simvastatin treatment normalized baroreflex regulation of heart rate in response to hypotension.
Conclusions:
- Non-lipid-lowering effects of statins include normalization of sympathetic outflow in CHF.
- Simvastatin improves autonomic regulation and baroreflex function in experimental CHF.
- These findings suggest a potential new therapeutic strategy for managing CHF progression.
Keywords:
Non-programmatic
Related Concept Videos
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...